Core Viewpoint - The company, 大东方, reported a stable stock price with a closing price of 4.79 yuan as of June 6, 2025, and a total market capitalization of 4.238 billion yuan, ranking 40th in the retail sector and 3387th in the A-share market [1] Company Announcements Summary - The company responded to the Shanghai Stock Exchange regarding the 2024 annual report inquiry, stating that the long-term equity investment balance is 2.486 billion yuan, with no impairment recorded [1][4] - Major investment targets include companies involved in real estate leasing, new materials development, automotive retail and maintenance, new energy vehicle investment, and real estate development and sales [1][2] - The company disclosed that the balance of other receivables for 2022 to 2024 was 60 million yuan, 9 million yuan, and 111 million yuan respectively, detailing the top five occurrences [2][3] Medical Health Business Performance - The overall revenue for the medical health business in 2024 is projected to be 2.838 billion yuan, reflecting a year-on-year growth of 8.16% with a gross margin of 7.55% [2][4] - The pediatric growth and development medical service segment benefited from the expansion of pediatric outpatient institutions and increased sales of growth hormone drugs, achieving a revenue growth of 10.33% year-on-year [2][4]
每周股票复盘:大东方(600327)2024年报问询函回复,医疗健康业务收入增长8.16%